HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ — Ascletis Pharmaceuticals (Hong Kong Stock Exchange stock code: 1672, “Ascletis”) announced today that Dr. Jinzi Wu, founder, chairman and CEO of Ascletis, was invited to attend the 10th International Symposium on the Cure of Hepatitis B in Boston, USA. and give a speech.
Dr. Wu was invited to participate in sub-forum 3: Clinical Immunology and Immunotherapy Updatea lecture titled “Efficacy and Safety of Monoclonal Antibodies Targeting PD-L1.”
Ascletis recently announced positive interim data from a Phase IIb expansion cohort of the subcutaneous PD-L1 antibody ASC22 (Envafolimab) for functional cure of chronic hepatitis B. The interim analysis included 25 patients who completed 24 weeks of treatment (19 patients in the ASC22 cohort and 6 patients in the placebo cohort). Topline results showed that in the ASC22 cohort, 4 patients (4/19, 21.1%) achieved HBsAg loss at the end of 24 weeks of treatment. In contrast, no patients in the placebo group (0/6, 0%) achieved HBsAg loss at the end of 24 weeks of treatment. ASC22 was generally safe and well tolerated. Most ASC22 drug-related adverse reactions were grade 1 or 2.
Representatives from Roche, GlaxoSmithKline, Gilead, Immunocore, VIR, Arbutus, Aligos and other companies, as well as the National Institutes of Health, the University of Oxford, Massachusetts General Hospital, Johns Hopkins University, Université Lyon 1, and the University of Hong Kong , experts from the Toronto Liver Center, Emory University AIDS Research Center, Harvard Medical School, Northwestern University, and the University of Milan also participated in the meeting. Ascletis was the only Chinese biotech company to attend the conference.
Chronic hepatitis B remains a serious unmet medical need globally, with approximately 86 million people in China and 1.59 million people in the United States infected with hepatitis B virus (HBV) (1).
“It is an honor to be invited to participate in the 10th International Symposium on Hepatitis B Cure in 2023 and share our latest progress in developing immune checkpoint inhibitors for functional cure of chronic hepatitis B with the global industry. ASC22 is a global The most advanced clinical stage immunotherapy achieves functional cure of CHB by blocking the PD-1/PD-L1 pathway, that is, HBsAg disappears, and the number of patients with HBsAg ≤ 100 IU/mL is huge, accounting for approximately 15%-22% of the total number of patients. (twenty three). We will continue to accelerate clinical research on ASC22 to benefit patients with chronic hepatitis B. ” said Dr. Wu Jinzi, founder, chairman and CEO of Ascletis.
|
(1)Lim JK, Nguyen MH, Kim WR, et al. Prevalence of chronic hepatitis B virus infection in the United States (J). American Journal of Gastroenterology 2020, 115(9): 1429-38.
|
|
(2) Xie Y., Li Ming, Ou X. et al. HBeAg-positive patients with HBsAg < 100 IU/mL and HBV RNA negative are at lower risk for virologic relapse after discontinuation of nucleos |
|
(3) Kara S. Coffin et al. “Clinical outcomes and quantitative HBV surface antigen levels in diverse Canadian patients with chronic hepatitis B: the retrospective real-world study of chronic hepatitis B in Canada (REVEAL-CANADA).” Virus roll. 14.12 2668. November 29, 2022
|
International symposium on hepatitis B treatment
Since 2014, the International Hepatitis B Cure Symposium has been a scientific platform that serves as a catalyst to accelerate progress toward a cure. More than 250 million people worldwide are living with hepatitis B (HBV). The purpose of the workshop was to inform participants about the progress of work on hepatitis B treatments. The meeting was highly interactive with experts from beyond the fields of basic, translational and clinical hepatitis B research. The 10th International Symposium on Hepatitis B Treatment 2023 will be held as an on-site symposium in Boston, USA on November 8, 2023.
About Songli
Ascletis is an innovative R&D-driven biotech company listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and proven track record, Ascletis focuses on three therapeutic areas with unmet medical need from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and Oncology. Through superior execution, Ascletis rapidly advances its pharmaceutical pipeline and strives to stay ahead of global competition. Ascletis has multiple drug candidates in its pipeline to date. The most advanced drug candidates include ASC22 (CHB functional cure), ASC40 (acne), ASC40 (relapsed glioblastoma), ASC40 (NASH), ASC41 (NASH) and ASC61 (advanced solid tumors).
For more information, please visit www.ascletis.com.
View original content: https://www.prnewswire.com/news-releases/dr-jinzi-j-wu-presents-at-the-10th-international-workshop-on-hbv-cure-2023-301981460.html
SOURCE Ascletis Pharmaceuticals, Inc.
Company code: Hong Kong: 1672